Drugs / rFSAV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03966040 | May → Dec 2019 | staphylococcus aureus infection | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rFSAV | “we evaluated the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in healthy adults.” PMID 35473663 ↗ Apr 2022 |
| Known as | recombinant five-antigen Staphylococcus aureus vaccine | “we evaluated the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in healthy adults.” PMID 35473663 ↗ Apr 2022 |
| Modality | Vaccine | “a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV)” PMID 35473663 ↗ Apr 2022 |